^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NECTIN4 expression

i
Other names: NECTIN4, Nectin Cell Adhesion Molecule 4, Nectin-4, LNIR, PRR4, Poliovirus Receptor-Related Protein 4, Poliovirus Receptor-Related 4, Ig Superfamily Receptor LNIR, PVRL4, Nectin 4, EDSS1
Entrez ID:
Related biomarkers:
8d
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies (clinicaltrials.gov)
P1/2, N=329, Recruiting, BicycleTx Limited | N=172 --> 329 | Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Dec 2025
Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
EGFR mutation • ALK fusion • NECTIN4 expression
|
Keytruda (pembrolizumab) • BT8009
1m
Nectin-4 is widely expressed in head and neck squamous cell carcinoma. (PubMed, Oncotarget)
Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. Moreover, expression of Nectin-4 is associated with HPV infection and may serve as a prognostic marker in HNSCC.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
1m
Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression. (PubMed, Pathol Res Pract)
However, there was a significant decrease in Nectin-4 expression in post-neoadjuvant chemotherapy radical cystectomy specimens compared to pre-neoadjuvant chemotherapy transurethral resection specimens (P = 0.008). Given the downregulation of Nectin-4 by chemotherapy and the significant discrepancy between radical cystectomy and matched lymph node metastasis specimens, baseline primary tumors may not be a suitable material for evaluating Nectin-4 expression and its potential as a predictive biomarker for enfortumab vedotin treatment.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
1m
68Ga-N188 PET/CT Imaging in Malignancy (clinicaltrials.gov)
P=N/A, N=43, Recruiting, Peking University First Hospital
New trial
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
2ms
A Nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses (SITC 2022)
Animals in which Nectin-4 TRAAC treatment led to tumor clearance were protected from tumor growth upon rechallenge, demonstrating that Nectin-4 TRAAC induces potent anti-tumor immunological memory. Conclusions The preclinical data shown here provide a strong rationale for pursuing Nectin-4 TRAAC for the treatment of Nectin-4-expressing solid tumors, including those that are refractory to CPI therapy.
IO biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Nectin-4 TRAAC
2ms
BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy (SITC 2022)
1 The first molecule of this class, BT7480, a Nectin-4-dependent CD137 (4-1BB) agonist, entered clinical trials in 2021 in patients with solid tumors associated with Nectin-4 expression...The kinetics and extent of the immune microenvironment modulation differentiated BT7455 from both a checkpoint inhibitor (anti-mouse PD-1) as well as an anti-CD137 agonist antibody (Urelumab analogue)...Conclusions BT7455 is a highly potent EphA2 expression-dependent CD137 agonist with optimal target binding, pharmacologic, and pharmacokinetic properties that enable intermittent dosing for curative effect through modulation of the tumor immune microenvironment in syngeneic mouse models. BT7455 is currently being evaluated in IND-enabling safety studies.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • EPHA2 (EPH receptor A2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
MET overexpression • NECTIN4 expression • NFKB1 expression
|
BT7455 • BT7480 • urelumab (BMS-663513)
2ms
Gene expression of Nectin-4 and its clinical significance in dogs with primary lung adenocarcinoma. (PubMed, Vet Med Sci)
Our study demonstrated that Nectin-4 is highly expressed in CPLA. In addition, nectin-4 might be a tumour growth factor in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnosis and novel targets for oncolytic virotherapy.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
2ms
Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value-Need for Biomarker Testing in High-Risk Patients? (PubMed, Cancers (Basel))
However, the high expression of Nectin-4 in SCC and ADENO might guide future treatment with novel Nectin-4-directed ADCs and provide this high-risk patient collective with a new promising therapeutic option. Testing Nectin-4 expression as a biomarker should be considered in trials with SARCO, where low Nectin-4 expression has been observed.
Journal • Biomarker testing
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • NECTIN4 underexpression
2ms
Expression of nectin-4 in papillary renal cell carcinoma. (PubMed, Discov Oncol)
Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
2ms
BT8009; a Nectin-4 targeting Bicycle® Toxin Conjugate for treatment of solid tumors. (PubMed, Mol Cancer Ther)
Multiple tumor types overexpress Nectin-4 and the Antibody Drug Conjugate (ADC), enfortumab vedotin (EV) shows striking efficacy in clinical trials for metastatic urothelial cancer, which expresses high levels of Nectin-4, validating Nectin-4 as a clinical target for toxin delivery in this indication. These physical and PK characteristics differentiate BT8009 from ADCs and may provide benefit in terms of tumor penetration and reduced systemic exposure. BT8009 is currently in a Phase 1/2 multicenter clinical trial across the USA, Canada and Europe, enrolling patients with advanced solid tumors associated with Nectin-4 expression.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin) • BT8009
3ms
Nectin4 as a novel prognostic marker for endometrial carcinoma (ESGO 2022)
Our results indicate that Nectin4 is a novel diagnostic marker for EC, and their high expression in MSH2 deficient EC predicts a worse outcome of disease-free survival. These results may provide clues in identifying EC patients for adjuvant therapy.
MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • NECTIN4 underexpression • MSH6 expression
4ms
Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p. (PubMed, Cancer Cell Int)
Nectin-4 as an oncogene can promote OS progression and metastasis by activating PI3K/AKT/NF-κB signaling via down-regulation of miR-520c-3p, which could represent a novel avenue for identifying a potential therapeutic target for improving patient outcomes.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • RELA (RELA Proto-Oncogene)
|
NECTIN4 expression
4ms
NECTIN4 expression in sebaceous and sweat gland carcinoma (PubMed, Eur J Dermatol)
All tumours exhibited positive staining at least in a part of the lesion, and the mean H-score, a semiquantitative score ranging from 0 to 300, was 259.4 for sebaceous carcinoma and 253.1 for sweat gland carcinoma. Our results suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with NECTIN4-targeted antibody-drug conjugates, such as enfortumab vedotin.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
4ms
Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts (ESMO 2022)
Higher Nectin-4 expression in the BCP cohort could be a sign of an altered anti-tumour response. These results suggest differences in tumour proliferation and tumour/host immunogenicity in BCP cohort vs non-pregnant BC cohort.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
PD-L1 expression • NECTIN4 expression
|
PD-L1 IHC 22C3 pharmDx
5ms
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. (PubMed, Virchows Arch)
Recently, enfortumab vedotin, targeting cancer-associated NECTIN4, has been approved for the treatment of advanced urothelial carcinoma...Moreover, higher NECTIN4 heterogeneity was observed in patients with multifocal mixed TaHG tumors (22% of patients) compared to patients with multifocal CIS/T1HG and pure TaHG/T1HG tumors (9% and 5%). Taken together, NECTIN4-directed antibody-drug conjugates might be promising for the treatment of HR NMIBC patients, especially for those exhibiting CIS/T1HG and pure TaHG/T1HG tumors without a history of low-grade disease.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
6ms
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=208, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
Enrollment open • Trial initiation date
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
9MW2821
6ms
Stimulatory role of nectin-4 and p95-ErbB2 in multilayered T47D cell proliferation. (PubMed, Genes Cells)
We previously showed using T47D human mammary cancer cells that nectin-4, upregulated in many cancer cells, cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, p95-ErbB2 and ErbB2ΔEx16, and enhances DNA synthesis mainly through the PI3K-AKT pathway in an adherent culture...The AJC and apicobasal polarity were disorganized in T47D cells in a monolayer and T47D cells stably expressing both nectin-4 and p95-ErbB2 in multilayers. These results indicate that nectin-4 and p95-ErbB2 play a stimulatory role in multilayered proliferation in an adherent culture.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • SOX2 • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 expression • NECTIN4 expression • SOX2 expression
|
Herceptin (trastuzumab)
6ms
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. (PubMed, Expert Rev Anticancer Ther)
Enfortumab vedotin-ejfv has shown promising efficacy and safety in pretreated patients with advanced urothelial carcinoma. It is currently being evaluated in clinical trials in earlier lines of treatment and in combination therapy.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
6ms
Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. (PubMed, J Nanobiotechnology)
mAb-based radioimmunoimaging provides visualization tools for the stratification and diagnosis for TNBC, and the corresponding mAb-mediated PTT shows a powerful anti-tumor effect. Our findings demonstrate that this Nectin-4 targeting strategy offers a simple theranostic platform for TNBC.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
7ms
Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. (PubMed, Front Oncol)
Antibody-drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). Variant histology types included 72UC, 10 squamous carcinomas, 23 glandular carcinomas, 19 small cell carcinomas, 19 micropapillary variants, and 18 nested variants. NECTIN-4 expression was found to be 57/72 (79.2%), 10/10 (100%), 15/23 (65.2%), 4/19 (21.1%), 15/19 (78.9%), and 16/18 (88.9%) in conventional UC, squamous carcinoma, glandular carcinoma, small cell carcinoma, micropapillary, and nested variant, respectively, compared with 65/72 (90.3%), 8/10 (80.0%), 13/23 (56.5%), 3/19 (15.8%), 16/19 (84.2%), and 15/18 (83.3%) of TROP-2, and 26/72 (36.1%), 0, 5/23 (21.7%), 6/19 (31.6%), 5/19 (26.3%), and 7/18 (38.9%) of HER2.
Journal • Head-to-Head
|
HER-2 (Human epidermal growth factor receptor 2) • TROP2 (Trophoblast Cell Surface Antigen 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin)
7ms
Clinical • P1/2 data • IO biomarker
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
BT7480
7ms
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma. (PubMed, Sci Rep)
NECTIN4 knockdown inhibited the proliferation and angiogenesis of angiosarcoma cells, and Src kinase signaling was shown to be involved in NECTIN4 function, at least in part. NECTIN4-targeted therapy has the potential to be a novel treatment strategy for angiosarcoma.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
7ms
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. (PubMed, Oncologist)
Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) previously treated with a platinum-based chemotherapy and a programmed death receptor-1/programmed death-ligand 1 (PD-1/L1) inhibitor, or patients with la/mUC who are ineligible for cisplatin-based chemotherapy and have previously received one or more prior lines of therapy. There is the potential for rare but severe and possibly fatal cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis, as described in the boxed warning of the US prescribing information for enfortumab vedotin. This manuscript describes the presumed pathophysiology and manifestations of dermatologic reactions related to enfortumab vedotin, and presents recommendations for prevention and treatment, to provide oncologists and other healthcare providers with an awareness of these potential adverse events to best anticipate and manage them.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
NECTIN4 expression
|
cisplatin • Padcev (enfortumab vedotin)
8ms
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Silverback Therapeutics | N=225 --> 0 | Trial completion date: May 2025 --> Mar 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2025 --> Mar 2022
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 negative • NECTIN4 expression
|
Keytruda (pembrolizumab) • SBT6290
8ms
The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review. (PubMed, Mol Cancer Ther)
Nectin-4 emerge as a promising target for anti-cancer drugs development because of its central role in tumorigenesis, and lymphangiogenesis. Enfortumab vedotin targeting Nectin-4 demonstrated encouraging results and should be extended to other types of solid tumors.
Review • Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
9ms
Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study. (PubMed, BMC Cancer)
Our pilot study suggest a possible relationship between Nectin-4 and DNA MMR protein expression in UTUC and a clinically significant correlation between defective MMR phenotype and genomic instability. Because of the possible implications of these data for innovative treatment approaches, the need for further studies in this area is warranted.
Retrospective data • Journal • Mismatch repair
|
MSI (Microsatellite instability) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • MSH6 expression
9ms
Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA®) (AACR 2022)
The optimized method and dose-dependent detection of CD137+ cells and RO by BT7480 was further verified in unstimulated lung cancer patient whole blood samples (n=5). Results from this study represent the first report of a clinic-ready CD137 RO assay and the first flow cytometry assay using fluorescently labelled Bicycle® reagents and demonstrate the utility of the Bicycle® CD137 RO assay to monitor target engagement in the BT7480 first-in-human clinical trial.
P1/2 data • IO biomarker
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
BT7480
9ms
Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer (AACR 2022)
EV also has encouraging activity in combination with pembrolizumab in previously untreated la/mUC (73% ORR)(Friedlander 2021). In this preclinical model, increased levels of MMAE in the targeted bladder tissue were associated with increasing the total dose and concentration of EV more than changing either the volume instilled or dwell time. These findings provide evidence to support further investigation of intravesical EV in NMIBC patients.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Keytruda (pembrolizumab) • Padcev (enfortumab vedotin)
9ms
BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression (AACR 2022)
Here, we describe the preliminary monotherapy dose escalation results of the ongoing multicenter Phase I/II clinical trial (NCT04561362) that assesses the safety and tolerability of BT8009 administration in patients with advanced solid tumors associated with Nectin-4 expression, not exposed to enfortumab vedotin. BT8009 exhibits a promising preliminary tolerability profile and preliminary antitumor activity. The molecule will continue to be explored in the current dose-escalation/dose-expansion study of BT8009 monotherapy and in combination with nivolumab.
Clinical • P1/2 data • PD(L)-1 Biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Opdivo (nivolumab) • Padcev (enfortumab vedotin) • BT8009
9ms
Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 negative • NECTIN4 expression
|
Keytruda (pembrolizumab) • SBT6290
9ms
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. (PubMed, Eur Urol Oncol)
Overall, TROP2 gene expression is higher than NECTIN4 gene expression, and cells resistant to enfortumab vedotin (EV), a NECTIN4-targeting antibody-drug conjugate, remain sensitive to sacituzumab govitecan (SG). Our findings suggest that SG may be effective across most bladder cancer subtypes, including the bladder cancers previously treated with EV.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
TROP2 expression • NECTIN4 expression
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin)
10ms
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 (clinicaltrials.gov)
P1, N=213, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
Trial completion date • Trial primary completion date
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
10ms
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma. (PubMed, Cancers (Basel))
TROP-2 and nectin-4 are potential therapeutic targets for ATC undifferentiated from papillary thyroid carcinoma and de novo ATC, respectively. GPNMB and B7-H3 potential for treating all types of ATC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD276 (CD276 Molecule) • TROP2 (Trophoblast Cell Surface Antigen 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GPNMB (Glycoprotein Nmb)
|
HER-2 negative • NECTIN4 expression
10ms
New P1/2 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 negative • NECTIN4 expression
|
Keytruda (pembrolizumab) • SBT6290
10ms
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=208, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
New P1/2 trial
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
9MW2821
11ms
Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology. (ASCO-GU 2022)
Although there is heterogeneity, our results showed expression of Nectin-4 and PD-L1 in this cohort of patients with BCVH. These findings highlight the therapeutic potential of antibody-drug conjugates against Nectin-4- and anti PD1/PD-L1-based therapy in this population. Additional analysis including clinical outcomes and genomic analyses are ongoing, and a prospective clinical trial is planned.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
PD-L1 expression • NECTIN4 expression
|
PD-L1 IHC 22C3 pharmDx
11ms
NECTIN-4 AND DNA MISMATCH REPAIR PROTEINS EXPRESSION IN UPPER URINARY TRACT TUMORS: AN INNOVATIVE MODEL FOR TUMOR TARGETING APPROACHES? AN IMGO PILOT STUDY (AIOM 2021)
This analysis provides a molecular description of UTUC and found a relationship between Nectin-4 and DNA MMR proteins expression. We identified also a clinically significant correlation between defective MMR phenotype and genomic instability.
Clinical • Mismatch repair
|
MSI (Microsatellite instability) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • MSH6 expression